Patricia Bedard, PhD is a Director and Treasurer at Berkeley Pharma Tech Foundation, joining the board in the fall of 2025. She is a translational research and development scientist with over 30 years of experience supporting clinical development with nonclinical studies that predict and explain how human therapeutics act and through identification of treatment biomarkers.

Dr. Bedard has worked in both large pharmaceutical and smaller biotechnology firms, developing expertise across multiple treatment modalities, including small molecules, proteins, and cell-based therapies, and wide range of disease areas such as glomerular and cardiovascular diseases, alcoholic liver disease, and inflammatory conditions. She has contributed to every phase of drug development, from high-throughput screening to FDA label negotiations, and was part of the team that successfully licensed Filspari (sparsentan) in the United State and Europe for adults with IgA nephrology, a rare kidney disease.

Dr. Bedard earned a Bachelor of Science in Biochemistry from Northeastern University and PhD in Pharmacology from Boston University Medical School. She recently discovered a hidden talent for painting pet portraits.